Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $39.89.

KYMR has been the topic of several research reports. Bank of America lowered shares of Kymera Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $45.00 to $30.00 in a report on Wednesday, January 3rd. Wolfe Research initiated coverage on shares of Kymera Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating on the stock. Piper Sandler lifted their price objective on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Truist Financial raised their target price on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, JPMorgan Chase & Co. raised their target price on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd.

Kymera Therapeutics Trading Up 0.1 %

KYMR stock opened at $40.20 on Friday. Kymera Therapeutics has a 12 month low of $9.60 and a 12 month high of $45.31. The company has a 50-day moving average price of $37.91 and a 200 day moving average price of $25.74. The stock has a market cap of $2.46 billion, a PE ratio of -15.95 and a beta of 2.30.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.19. The company had revenue of $47.90 million during the quarter, compared to analysts’ expectations of $41.94 million. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The firm’s quarterly revenue was up 197.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.60) EPS. Sell-side analysts forecast that Kymera Therapeutics will post -3.16 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In other news, Director Bruce Booth sold 71,764 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the completion of the sale, the director now owns 806,697 shares of the company’s stock, valued at $32,638,960.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $42.23, for a total transaction of $4,860,250.70. Following the completion of the sale, the insider now owns 4,676,075 shares of the company’s stock, valued at approximately $197,470,647.25. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bruce Booth sold 71,764 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the sale, the director now directly owns 806,697 shares of the company’s stock, valued at approximately $32,638,960.62. The disclosure for this sale can be found here. Insiders sold 487,346 shares of company stock valued at $19,999,112 over the last 90 days. Corporate insiders own 16.67% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KYMR. State Street Corp boosted its holdings in Kymera Therapeutics by 67.8% in the 2nd quarter. State Street Corp now owns 3,514,438 shares of the company’s stock valued at $69,199,000 after purchasing an additional 1,419,877 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Kymera Therapeutics by 34.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,224,686 shares of the company’s stock valued at $102,874,000 after purchasing an additional 1,329,481 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Kymera Therapeutics by 19.7% in the 1st quarter. Wellington Management Group LLP now owns 3,225,749 shares of the company’s stock valued at $136,514,000 after purchasing an additional 530,935 shares during the last quarter. Norges Bank acquired a new position in Kymera Therapeutics in the 4th quarter valued at about $12,834,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Kymera Therapeutics by 229.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock valued at $17,177,000 after purchasing an additional 469,947 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.